The present invention relates to the use of PDGF receptor tyrosine kinase
or bcr-abl tyrosine kinase inhibitors, especially of
N-phenyl-2-pyrimidine-amine derivatives of formula I, in which the
symbols and substituents have the meaning as defined herein in free form
or in pharmaceutically acceptable salt form, in the manufacture of a
pharmaceutical composition for the treatment of tuberous sclerosis
associated neoplasms; to a method of treatment of warm-blooded animals,
including humans, suffering from a tuberous sclerosis associated
neoplasms.